Helen Torley

This profile gathers the share dealings of Helen Torley across 2 companies, led by Halozyme Therapeutics, Inc. and Quest Diagnostics Inc. In total, 94 filings cover trades dated from 31 December 2015 to 8 October 2026.

Sales make up the whole of the open-market record (32 sales, €17.0M). Outside the open market, there are 5 share grants and 54 option exercises. Since January 2026: no purchases and 32 sales on the market.

On 8 October 2026 came the latest disclosure, an option exercise for €328k in Halozyme Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.